| Document |
Document Title |
|
WO/2023/171894A1 |
The present invention relates to a pharmaceutical composition including docetaxel and a pharmaceutically acceptable salt thereof and a preparation method therefor. The present invention relates to a composition capable of increasing the ...
|
|
WO/2023/170585A1 |
The present invention relates to crystalline salts of (R)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]
indol-3-yl)acetic acid, and pharmaceutical compositions comprising them that are useful as S1P1...
|
|
WO/2023/169073A1 |
The present invention relates to the technical field of medical materials. Provided in the present disclosure are a periodontal topical delivery preparation, and a preparation method therefor and the use thereof. The method for preparing...
|
|
WO/2023/167563A1 |
The present invention relates to a method for biosynthesizing N-carbamyl-L-glutamic acid and a novel use thereof for the prevention or treatment of inflammatory diseases. The invention also relates to a composition for the prevention, am...
|
|
WO/2023/167066A1 |
[Problem] To find a novel pharmaceutical or method for treating autoimmune diseases. [Solution] A combination of methotrexate and 5-ALAs.
|
|
WO/2023/165551A1 |
The present application relates to a six-membered aromatic ring-pyrrolidone derivative, and a pharmaceutical composition thereof and the use thereof. The six-membered aromatic ring-pyrrolidone derivative has the structure as shown in for...
|
|
WO/2023/166206A1 |
The present invention provides an IL-18 inhibitor for use in the treatment of VEXAS syndrome or symptoms associated with VEXAS syndrome in a subject.
|
|
WO/2023/165477A1 |
The present invention relates to a nucleic acid molecule encoding an interleukin 1 receptor antagonist protein, a transgenic expression cassette comprising the nucleic acid molecule, a gene delivery system comprising the transgenic expre...
|
|
WO/2023/168087A1 |
The present disclosure provides methods and compositions that involve inhibiting an activity of epiregulin in a cell, as well as reversing or preventing a change(s) in a cell, associated with a disease or disorder, e.g., a fibrotic disea...
|
|
WO/2023/133634A9 |
Described herein are cell populations comprising leukocyte lineage cells expressing one or more of CD16 and/or CD11b loaded with an agent, optionally an imaging agent, biologic or synthetic therapeutic, their method of making and their u...
|
|
WO/2023/097398A9 |
A composition is provided for treating and/or preventing inflammation in a subject comprising A-type proanthocyanidin (PAC-A) and zinc. The composition can include between 0.001 wt% and 10 wt% of PAC-A, and between 0.01 wt% and 25 wt% of...
|
|
WO/2023/164847A1 |
The present invention provides a combinational anti-cancer therapy with a CTLA-4 inhibitor and a non-steroidal anti-inflammatory drug. Specifically, the present invention provides a product combination comprising: (i) a first pharmaceuti...
|
|
WO/2023/168367A1 |
The present disclosure provides compounds that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.
|
|
WO/2023/165570A1 |
The present invention relates to a compound of formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutical composition thereof, and a use of the compound...
|
|
WO/2023/165574A1 |
Disclosed are a compound used as a TYK2 inhibitor, a preparation method therefor, and pharmaceutical use thereof. Specifically, the compound has a structure represented by formula (I), wherein the definitions of the groups and substituen...
|
|
WO/2023/165554A1 |
The present application relates to the technical field of chemical drugs, and relates to a deuterated compound represented by general formula (I), or a racemate thereof, or an isomer thereof, or a pharmaceutically acceptable salt thereof...
|
|
WO/2023/160405A1 |
Provided is a compound NMNH disodium salt, and the present invention in particular relates to a polymorph of a reduced β-nicotinamide mononucleotide disodium salt, and a preparation method therefor and the use thereof as a pharmaceutica...
|
|
WO/2023/163539A1 |
The present invention relates to a use of a novel pomalidomide derivative which is for treating brain diseases, and exhibits improved pharmacological effects as compared to pomalidomide. The novel pomalidomide derivative according to the...
|
|
WO/2023/161938A1 |
A pharmaceutical composition is described herein, which comprises a therapeutically active agent, an absorption enhancer, and a polymer comprising a plurality of alkaline groups. The therapeutically active agent is a peptide which is a k...
|
|
WO/2023/164680A1 |
Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditi...
|
|
WO/2023/159277A1 |
A pharmaceutical composition comprising a cannabinoid; and a polyethylene glycol (PEG) ester.
|
|
WO/2023/163538A1 |
The present invention relates to: a novel pomalidomide derivative exhibiting effects better than those of pomalidomide; a preparation method therefor; and use thereof. The novel pomalidomide derivative according to the present invention ...
|
|
WO/2023/160566A1 |
Provided is a functional subgroup of umbilical cord mesenchymal stem cells that has a high-expression marker on the surface of cells. The marker not only comprises widely recognized CD105, CD73 and CD90, but also comprises newly discover...
|
|
WO/2023/161881A1 |
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as...
|
|
WO/2023/161291A1 |
The present invention relates to a peptide linker comprising (a) an amino acid residue comprising a primary amine; and (b) two or more payloads; wherein each of the two or more payloads can be independently attached to: (i) an N-terminal...
|
|
WO/2023/160509A1 |
Provided in the present invention are an amidine derivative compound as represented by formula I, and a preparation method therefor and the use thereof. The amidine derivative compound of the present invention has Nav1.8 selective inhibi...
|
|
WO/2023/161227A1 |
The present invention relates to a complex coacervate comprising lactoferrin and osteopontin, processes of producing the same and composition comprising the same. Moreover, the present invention relates to complexes comprising lactoferri...
|
|
WO/2023/159296A1 |
The present application relates to methods of treating urologic chronic pelvic pain syndrome (UCPPS) or pain associated with UCPPS using a compound of Formula I, or a pharmaceutically acceptable salt, prodrug and/or solvate thereof. UCPP...
|
|
WO/2023/160638A1 |
This disclosure provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, e. g., including those mediated by receptor-interacting protein ...
|
|
WO/2023/164250A1 |
Provided herein are secretion inhibitors, such as inhibitors of Sec61 having a structure of formula (I): methods for their preparation, related pharmaceutical compositions, and methods for using the same.
|
|
WO/2023/161327A1 |
The present invention relates to improved methods for the use of the compound according to Formula (I) in the treatment of inflammatory diseases, and/or diseases associated with hypersecretion of INFα and/or interferons ("interferonopat...
|
|
WO/2023/164057A1 |
The disclosure herein provides compounds and pharmaceutical compositions of Formula (I) for the modulation of IL-17A. Compounds and pharmaceutical compositions of Formula (I) are useful for the treatment of inflammatory conditions, such ...
|
|
WO/2023/163470A1 |
The present invention relates to an injectable formulation comprising, as an active pharmaceutical ingredient (API), an isoxazoline derivative or a pharmaceutically acceptable salt thereof, which are useful as caspase inhibitors. The inj...
|
|
WO/2023/089502A9 |
The invention relates to a peptide drug for use as a localized antimicrobial agent and/or in the localised modulation of nerve cell activity, cardiomyocyte or muscle cell electrical activity in a subject, wherein the peptide drug compris...
|
|
WO/2023/161323A1 |
The present disclosure relates to polypeptides and polypeptide analogues derived from Annexin A1 as well as compositions comprising said polypeptides or polypeptide analogues for treatment of inflammatory and ischemic conditions.
|
|
WO/2023/162447A1 |
Provided is a poultice including a support layer and an adhesive layer, wherein the adhesive layer contains a silicic anhydride, a drug, a water-soluble polymer, and at least one type of substance selected from the group consisting of ca...
|
|
WO/2023/156768A1 |
The present disclosure provides compositions which may be useful in the generation of vitamin D and/or nitric oxide, in particular when exposed to radiation (e.g. light and/or UV radiation). The disclosure further provides methods of gen...
|
|
WO/2023/155315A1 |
Provided is a preparation method of a Piper nigrum L. essential oil with anti-inflammatory activity, which comprises: performing ultralow-temperature freezing, microwave thawing, pulp grinding, enzymolysis, steam distillation, and oil-wa...
|
|
WO/2023/155757A1 |
Provided is use of sarsasapogenin compounds in the preparation of a medicine for treating related diseases caused by mitochondrial dysfunction, wherein the structural formula of the compounds is shown in general formula (I). The activity...
|
|
WO/2023/157948A1 |
The present invention addresses the problem of providing a novel lipid functional ingredient that can be taken or administered orally. An example of a composition containing said ingredient is a composition containing glycerol-1-phosphat...
|
|
WO/2023/158933A1 |
The present invention includes a method of treating a subject having relapsing-remitting multiple sclerosis (RRMS) that is undergoing relapse, comprising: determining a level of expression for two or more biomarkers selected from urokina...
|
|
WO/2023/158178A1 |
Disclosed are a peptide having antibacterial, anti-inflammatory, or tissue regeneration ability and use thereof. The peptide comprises an amino acid sequence of SEQ ID NO: 1.
|
|
WO/2023/155837A1 |
PHARMACEUTICAL COMPOSITION HAVING ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND USE THEREOF The composition contains a Nav1.7 inhibitor and a Nav1.8 inhibitor, and the weight ratio of the Nav1.7 inhibitor to the Nav1.8 inhibitor is 1:(0.00...
|
|
WO/2023/158708A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2023/159154A1 |
Disclosed are compounds of Formulas (I): (Formulas (I)) or a salt thereof, wherein X, Y, Q, G, R1, and R5a are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comp...
|
|
WO/2023/158824A1 |
This application relates to novel bicyclic substituted sulfonylurea compounds of formula (I), their manufacture, pharmaceutical compositions comprising them, and their use as medicaments for treating a disease associated with modulation ...
|
|
WO/2023/159120A1 |
The present disclosure relates to methods for treating hidradenitis suppurativa with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1, 4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (I) or a pha...
|
|
WO/2023/157891A1 |
The present invention addresses the problem of providing a drug for use in the treatment of triple-negative breast cancer, providing a blood marker for triple-negative breast cancer, and providing a drug for use in the treatment of infla...
|
|
WO/2023/158242A1 |
Provided are a polypeptide having hair loss treating or hair growth promoting activity and use thereof.
|
|
WO/2023/158024A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising an Isodon excisus (Max.) Kudo-derived compound as an active ingredient. A compound represented by chem...
|
